Clinical Trials

Blue virus 3d image in attractive colour background.
Hand,Drawn,Watercolor,Virus,Illustration:,Coronavirus,2019-ncov.,Green,Ball,With
Blue virus 3d image in attractive colour background.

COVID-19, Schizophrenia, Dementia And Depression

SyneuRx is conducting several late-phase clinical trials in COVID-19 and schizophrenia disease areas. 

Trials for dementia and depression will be launched in the near future

Watercolor drawing of the coronavirus epidemic. Covid-19 quarantine illustration

This is a Phase 2 trial testing the safety and efficacy of Pentarlandir for early and mildly symptomed COVID-19 patients. The antiviral efficacy for Pentarlandir covers different variants of COVID-19 since Pentarlandir targets two essential conservative enzymes during virus replication.

Print

This is a Phase 2/3 trial testing the safety and efficacy of NaBen as a add-on therapy for adult schizophrenia. The trial is currently ongoing in the US, EU, and Taiwan.

NaBen is a DAAO inhibitor with a well-established safety profile and has been proved to enhance the function of NMDA receptors through reducing the metabolism of D-amino acid. NaBen is the first breakthrough therapy designation for schizophrenia approved by the US FDA. 

Print

This is a Phase 2/3 trial testing the safety and efficacy of NaBen as a add-on therapy for adults schizophrenia who are not responding to at least 2 existing antipsychotics. The trial is currently ongoing in the US, EU, and Taiwan. 

NaBen is a DAAO inhibitor with a well-established safety profile and has been proved to enhance the function of NMDA receptors through reducing the metabolism of D-amino acid. The treatment for refractory schizophrenia is designed as NaBen plus clozapine. 

Print

This is a Phase 2/3 trial testing the safety and efficacy of NaBen as a add-on therapy for adolescent schizophrenia. The trial is currently ongoing in the US, EU, and Taiwan. 

NaBen is a DAAO inhibitor with a well-established safety profile and has been proved to enhance the function of NMDA receptors through reducing the metabolism of D-amino acid. NaBen treatment for adolescent schizophrenia has been granted as orphan drug by the US FDA.